Roles and challenges of traditional Chinese medicine in COVID-19 in Hong Kong

Hong Kong Med J 2020 Jun;26(3):268–9  |  Epub 5 Jun 2020
Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
LETTER TO THE EDITOR
Roles and challenges of traditional Chinese medicine in COVID-19 in Hong Kong
WL Lin, PhD, BChinMed1; KL Hon, MB, BS, MD1,2; Karen KY Leung, MB, BS, MRCPCH2; ZX Lin, BSc, PhD1
1 Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
2 Department of Paediatrics and Adolescent Medicine, The Hong Kong Children’s Hospital, Hong Kong
 
Corresponding author: Dr KL Hon (ehon@hotmail.com)
 
 Full paper in PDF
 
To the Editor—To date, there are no reported outbreaks of coronavirus disease 2019 (COVID-19) among traditional Chinese medicine (TCM) practitioners and their patients. Traditional Chinese medicine is popular globally, especially in Asian populations such as in Hong Kong. The concept of integrative medicine is appreciated by members of the public.1 2 Patients who do not want to be treated by Western medicine often seek TCM herbal remedies instead. Practitioners of TCM are confronted with infection control issues when they treat patients with mild and vague symptoms. Some TCM practitioners wear personal protective equipment, including mask and gown, to protect themselves during consultations. However, several routine TCM manoeuvres are high-risk. In TCM, the tongue is considered to have many relationships and connections in the body, both to the meridians and the internal organs. It is therefore considered essential and important to inspect the tongue for confirming TCM diagnoses. Pulse diagnosis also provides TCM practitioners with information about the health of their patients. In terms of treatment, many TCM procedures such as acupuncture, cupping, and moxibustion are considered high-risk. Various issues are encountered by TCM practitioners (Table3 4 5).
 

Table. Issues faced by Chinese medicine practitioners in COVID-19 pandemic in Hong Kong
 
There are currently over 10 000 TCM practitioners in Hong Kong, compared with 14 600 doctors of Western medicine. These TCM practitioners have an important role to contribute in sharing the health burden in the current COVID-19 pandemic, at least in diagnosing and treating mild cases. The role of TCM is now well established and the dispensation, storage, and labelling of Chinese herbal medicines has been regulated since 2003. In addition, TCM practitioners are regulated and there are plans for a Chinese Medicine Hospital in Tseung Kwan O.6 Although there is ongoing research into TCM treatment of COVID-19, the role of the discipline is limited and needs deliberation and recognition.3 4 5
 
In mainland China, the treatment protocol for diagnosis and treatment for novel coronavirus pneumonia has confirmed the integrative role of TCM in the management of COVID-19.7 Treatment is offered based on stages of disease, namely, pre-diagnosis, confirmed (mild, moderate, severe, and critical), and rehabilitation.7 As with many treatment strategies worldwide, trials are ongoing and there has been no current evidence to support or refute many of the novel treatments, neither in Western nor TCM.
 
The current policy of the Hong Kong SAR government is that all cases are centralised and managed in the public Hospital Authority system, exclusive of private sector or TCM partners. It is recommended that the Hong Kong SAR government may follow the policy in mainland China to provide TCM as a complementary treatment for in-patients with milder disease as part of the healthcare team responding to COVID-19. In addition, TCM can be offered to patients in the pre-diagnosis and rehabilitation periods for health promotion. There is nothing to lose when patients and citizens see that holistic or integrative medicine is provided by the public system. When further evidence of efficacy is established, TCM can be promoted in the other TCM clinics to serve the public.
 
The TCM practitioners in Hong Kong have important roles in treating patients with suspected COVID-19 in the community.
 
Author contributions
All authors contributed to the concept of the study, acquisition and analysis of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have no conflicts of interest to disclose.
 
Funding/support
This letter received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
References
1. Hon KL, Leung AK. Integrative, integrated medicine but no integration: Tarnishing steroid and Chinese medicine is vanity. Hong Kong J Paediatr 2018;23:192-4.
2. Hon KL, Leung AK, Leung TN, Lee VW. Complementary, alternative and integrative medicine for childhood atopic dermatitis. Recent Pat Inflamm Allergy Drug Discov 2017;11:114-24. Crossref
3. Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020;155:104743. Crossref
4. Chan KW, Wong VT, Tang SC. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med 2020;48:737-62. Crossref
5. Gray PE, Belessis Y. The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good. Pharmacol Res 2020;156:104776. Crossref
6. Hong Kong SAR government. Prequalification for operation of Chinese Medicine Hospital in Tseung Kwan O (with video). 13 September 2019. Available from: https://www. info.gov.hk/gia/general/201909/13/P2019091200691.htm. Accessed 4 May 2020.
7. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia; 2020. Available from: https://www.chinadaily.com.cn/pdf/2020/1.Clinical. Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19. V7.pdf. Accessed 4 May 2020.

Paediatrics is a big player of COVID-19 in Hong Kong

Hong Kong Med J 2020 Jun;26(3):265–6  |  Epub 5 Jun 2020
Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
LETTER TO THE EDITOR
Paediatrics is a big player of COVID-19 in Hong Kong
KL Hon, MB, BS, MD; Karen KY Leung, MB, BS, MRCPCH
Department of Paediatrics and Adolescent Medicine, The Hong Kong Children’s Hospital, Hong Kong
 
Corresponding author: Dr KL Hon (ehon@hotmail.com)
 
 Full paper in PDF
 
To the Editor—As of 23 April 2020, there have been 104 confirmed paediatric cases of coronavirus disease 2019 (COVID-19) in Hong Kong.1 Fortunately, all cases were mild or asymptomatic with no fatalities.1 The proportion of patients with COVID-19 who are aged ?19 years is 14.1% in Hong Kong, which is higher than other countries (Table).1 2 3 4 5 6 This may be attributable to high numbers of overseas students returning to Hong Kong; even those who are asymptomatic are tested as part of the current border controls. Mortality for patients aged ?19 years is very low, with less than 10 reported cases, mostly teenagers.7 8 9
 

Table. Patients with coronavirus disease 2019 (COVID-19) aged ?19 years (as of 22 Apr 2020)
 
Current clinical management of COVID-19 is mainly supportive and there are currently no definite antiviral drugs recommended for the treatment of paediatric patients with COVID-19.7 The Hong Kong College of Paediatricians and The Hong Kong Society of Paediatric Immunology Allergy and Infectious Disease have taken a leading role in paediatric public health promotions, and published a very clear and informative guidance for parents to refer to in prevention of COVID-19, with links to educational materials that will help children understand the current situation of this epidemic.10 Children should be engaged in usual preventive actions to avoid infection, including cleaning hands often using soap and water or alcohol-based hand sanitiser, avoiding contact with others who display COVID-19 symptoms, and staying up to date on vaccinations, including influenza vaccine.
 
In response to the COVID-19 pandemic, schools in Hong Kong were closed from 25 January 2020, resulting in psychosocial crises in schooling, examinations, and related childhood and paediatric routines.11 Many challenging decisions have been made to manage these crises while children are home-bound. Teaching has been partially resumed with online teaching, examinations have been postponed, modes of examinations have been modified, and formal schooling will only be resumed when there is evidence that the spread of COVID-19 is slowing or stopped. Although children fare better after infection, they may serve as vectors of viral transmission in the community. Specific interventions implemented to reduce such risks include quarantining and rigorous screening of asymptomatic or silent carriers. Isolation facilities have to be provided to contain and treat these relatively well infected patients, so that airborne infection isolation rooms can be reserved for more seriously affected patients. Although there is no robust evidence that lactating mothers spread the virus more easily than others, for those who are healthcare personnel working in high-risk areas, it may be prudent to switch them temporarily to lower-risk posts to reduce the risks of contracting the virus.
 
The next challenge for Hong Kong is to resume socio-economic activities whilst suppressing the outbreak of potential cases in the community. Children and young adults may be a big driver in the ‘second wave’ of the COVID-19 outbreak in Hong Kong, and appropriate measure should be taken to minimise this risk.
 
Author contributions
All authors contributed to the concept or design of the study, acquisition of the data, analysis or interpretation of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
The authors have no conflicts of interest to disclose.
 
Funding/support
This letter received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
References
1. Centre for Health Protection, Hong Kong SAR Government. Latest situation of cases of COVID-19. Available from: https://www.chp.gov.hk/files/pdf/local_situation_covid19_en.pdf. Accessed 23 Apr 2020.
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID- 19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42. Crossref
3. Ministry of Health Singapore. Official update of COVID- 19 situation in Singapore. 2020 Available from: https://covidsitrep.moh.gov.sg/. Accessed 29 Mar 2020.
4. Korean Centers for Disease Control and Prevention. The updates on COVID-19 in Korea as of 24 March. Available from: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=366633. Accessed 24 Mar 2020.
5. CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422-6. Crossref
6. Istituto Superiore di Sanita. Epidemia COVID-19 [in Italian]. Available from: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino sorveglianza integrata COVID-19_19-marzo 2020.pdf. Accessed 28 Mar 2020.
7. Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr 2020 Feb 7. Epub ahead of print. Crossref
8. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5. Crossref
9. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020 Mar 16. Epub ahead of print.
10. Hong Kong College of Paediatricians and Hong Kong Society for Paediatric Immunology Allergy and Infectious Diseases. Prevention of novel coronavirus infection, recommendations for parents. 5 February 2020. Available from: http://www.paediatrician.org.hk/index.php?option=com_docman&task=doc_view&gid=1768&Itemid=66. Accessed 22 Apr 2020.
11. Hong Kong SAR Government. SED opening remarks at press conference on measures against novel coronavirus infection. 25 January 2020. Available from: https://www.info.gov.hk/gia/general/202001/25/P2020012500583.htm. Accessed 10 May 2020.

Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm

Hong Kong Med J 2020 Jun;26(3):269–71  |  Epub 5 Jun 2020
Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
LETTER TO THE EDITOR
Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm
Karen KY Leung, MB, BS, MRCPCH1; KL Hon, MB, BS, MD1; SY Qian, MD2; Frankie WT Cheng, MB, ChB, MD1
1 Department of Paediatrics and Adolescent Medicine, The Hong Kong Children’s Hospital, Hong Kong
2 Pediatric Intensive Care Unit, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China
 
Corresponding author: Dr KL Hon (ehon@hotmail.com)
 
 Full paper in PDF
 
To the Editor—Two recent articles concerning corticosteroid usage in the coronavirus disease 2019 (COVID-19) pandemic provide opposing evidence and run the risk of muddying the waters on this controversial yet important topic.1 2 On the one hand, Russell et al1 tabulated a number of mainly observational clinical studies cautioning more harm than benefit with corticosteroid usage. On the other hand, Shang et al,2 acknowledging that existing evidence is inconclusive at best, referenced recommendations by Chinese physicians with frontline clinical experiences of COVID-19 who advocate short courses of corticosteroids at low-to-moderate doses for more severe disease.
 
In clinical settings, physicians tend to use corticosteroids only for treating critically ill patients. Therefore, selection bias and confounders in observational studies might contribute to any observed increased mortality in patient groups treated with corticosteroids. The papers cited by Russell et al1 omit to address coronavirus mortality, and the strength of the evidence presented does not support the certainty of the authors’ conclusions (Table).
 

Table. Adapted from cases reported by Russell et al1 with counter comments
 
Similar to respiratory viral diseases such as the seasonal influenza, two categories of people seem susceptible to die from COVID-19: older adults, especially those with chronic disease or other co-morbidities, and seemingly healthy adults with exacerbated autoinflammatory syndrome termed the cytokine storm syndromes.3 4 5 On the contrary, children and infants seem to survive epidemics of coronavirus infections with very mild disease.6
 
We acknowledge the potential risks associated with high-dose corticosteroids in treating COVID-19 pneumonia, and agree that corticosteroid usage should be avoided if there are other efficacious anti-inflammatory immunomodulating medications against the cytokine storm, such as intravenous immunoglobulin, interleukin-1 inhibitors, interleukin-6 inhibitors, and Janus kinase inhibitors.4 However, on the basis of recommendations by frontline Chinese physicians and local clinical experience during the severe acute respiratory syndrome epidemic, a short course of corticosteroids at low-to-moderate dose is probably justifiable for critically ill patients with hyperinflammation.7 8 Chinese researchers are running a prospective randomised controlled trial to review the efficacy and safety of corticosteroids.9 Until further evidence becomes available, whether to use corticosteroids or not remains controversial.
 
Author contributions
All authors contributed to the concept of the study, acquisition and analysis of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
The authors have no conflicts of interest to disclose.
 
Funding/support
This letter received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
References
1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5. Crossref
2. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395:683-4. Crossref
3. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41:145-51.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4. Crossref
5. Ng PC, Lam CW, Li AM, Wong CK, Cheng FW, Leung TF, et al. Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics 2004;113:e7-14. Crossref
6. Hon KL, Leung CW, Cheng WT, Chan PK, Chu WC, Kwan YW, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003;361:1701-3. Crossref
7. Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:183-4.
8. Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 2007;54:28-39. Crossref
9. US National Library of Medicine, US Government. Efficacy and Safety of Corticosteroids in COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04273321. Accessed 24 Mar 2020.

Workflow updates to maintain clinical services and reduce utilisation of personal protective equipment during the COVID-19 outbreak

Hong Kong Med J 2020 Jun;26(3):263–4  |  Epub 5 Jun 2020
Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
LETTER TO THE EDITOR
Workflow updates to maintain clinical services and reduce utilisation of personal protective equipment during the COVID-19 outbreak
Ken YT Lee, PhD1; Aggie WS Kwan, MPH1; TL Que, MB, BS, FHKAM (Pathology)2; Mandy MY Mak, MSc1
1 Department of Physiotherapy, Tuen Mun Hospital, Hong Kong
2 Department of Clinical Pathology, Tuen Mun Hospital, Hong Kong
 
Corresponding author: Dr Ken YT Lee (physioken@yahoo.com.hk)
 
 Full paper in PDF
 
To the Editor—In a general hospital, there are many clinical procedures involving aerosol-generating procedures (AGPs), such as bronchoscopy and other specific procedures involving airway care, that can induce the production of aerosols of various sizes, including droplet nuclei.1 According to the latest guidelines from the Centre for Health Protection of the Hong Kong SAR Government, the recommended personal protective equipment (PPE) for performing AGPs includes N95 respirator, eye protection, gown, gloves, and cap (optional).2 However, there was a severe and mounting disruption to the global supply of PPE amid the outbreak of coronavirus disease 2019 (COVID-19). In response, the Hospital Authority adjusted public hospital non-emergency services and non-essential services to focus manpower and resources.3 Reducing utilisation of PPE in various clinical services has become an issue of current concern at frontline and management levels.4 5
 
Physiotherapists often perform AGPs such as open suctioning of respiratory tract (including tracheostomy care). In the Physiotherapy Department of Tuen Mun Hospital, the workflow of chest physiotherapy service was reviewed and analysed to explore the possibility of AGPs being grouped and handled by a designated team of physiotherapists, and the service delivery process of chest physiotherapy was then re-designed. A designated AGP team was established in which a group of physiotherapists (8 in total, on rotation) solely delivering chest physiotherapy involving AGPs. The workload for the AGP team was centralised and managed with extended working hours to maximise the use of every N95 respirator. To facilitate the implementation of the new workflow and compliance of infection control measures, a patient care assistant was assigned to assist the physiotherapist in logistics and patient preparation prior to and after the treatment, to maximise work efficiency. Additional training was provided to the patient care assistant to enhance their competency in infection control measures. The patient care assistant also helped to ensure proper gowning procedures of the physiotherapist. The changes in workflow were well communicated and supported by all staff. The AGP team using the new workflow have been observed by the consultant microbiologist and the cluster infection control officer, and they have found that the new workflow fulfils the updated requirements of infection control.
 
Since implementing the new workflow in February 2020, consumption of PPE in the Physiotherapy Department has decreased substantially. The usage of N95 respirators decreased from approximately 60 pieces to eight pieces daily (>80% reduction), resulting in saving >1000 N95 respirators per month. Most importantly, such administrative change of workflow neither sacrificed the clinical service provision nor the occupational safety in performing high-risk AGPs. In addition to chest physiotherapy, the above measures may also be applicable to other clinical procedures involving AGP such as elective endotracheal intubation, bronchoscopy, and upper airway endoscopy.
 
Author contributions
All authors contributed to the concept of the study, acquisition and analysis of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Funding/support
This letter received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
References
1. World Health Organization. Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care. Available from: https://www.who.int/csr/resources/publications/WHO_CD_EPR_2007_6/en/. Accessed 19 Mar 2020.
2. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Recommended personal protective equipment (PPE) in hospitals/clinics under serious/emergency response level coronavirus disease (COVID-19). Available from: https://www.chp.gov.hk/files/pdf/recommended_ppe_for_nid_eng.pdf. Accessed 19 Mar 2020.
3. Hong Kong SAR Government. HA adjusts service provision to focus on combatting epidemic. Available from: https://www.info.gov.hk/gia/general/202002/10/P2020021000711.htm. Accessed 19 Mar 2020.
4. Hong Kong SAR Government. Protective gear supply ensured. Available from: https://www.news.gov.hk/eng/2020/03/20200313/20200313_180244_445.html. Accessed 19 Mar 2020.
5. Wong DH, Tang EW, Njo A, et al. Risk stratification protocol to reduce consumption of personal protective equipment for emergency surgeries during COVID-19 pandemic. Hong Kong Med J 2020 May 5. Epub ahead of print Crossref

Pages